SeedFolio

SeedFolio is a venture capital firm based in San Diego, California, focusing on early-stage investments in companies developing innovative technologies aimed at conquering disease and promoting environmental sustainability. The firm seeks to generate significant benefits for patients and customers while achieving substantial profits for the company and its investors. SeedFolio employs a rigorous and systematic process to source and select companies with high reward-to-risk ratios.

The firm's investment strategy is geographically agnostic, with most investments in the United States, though it has made investments in and continues to evaluate non-U.S. companies. SeedFolio primarily invests at the seed stage, occasionally participating in Series A rounds and rarely in pre-seed stages. The firm is building a large portfolio, targeting about 50 companies, making approximately one investment per month. SeedFolio invests primarily in biotechnologies that conquer disease, including therapies and diagnostics, as well as B2B MedTech software, therapeutic medical devices, and some clean tech.

SeedFolio's typical investment size is $300,000, with a preference for priced rounds but occasional investments via convertible notes or SAFEs. The firm can efficiently lead priced rounds for U.S. companies where the total raise does not exceed $2 million. SeedFolio negotiates a board seat for investors, typically voted by all preferred investors and not held by a SeedFolio representative. The firm has law firms that can represent investors for a capped fee of $20,000 and typically shares a detailed deal memo on deals it leads.

After investing, SeedFolio provides ongoing support to its portfolio companies, including board representation, strategic guidance, and leveraging advisory partners for additional resources. The firm's managing director, Joe Gatto, brings experience as a founder and CEO with a successful exit, offering valuable insights and assistance to the companies it funds.

SeedFolio's portfolio includes companies such as HDAX Therapeutics, Vasa Therapeutics, Tiamat Sciences, VerImmune, Veckta, and Allotrope Medical, reflecting its commitment to supporting innovative ventures in the life sciences and resource efficiency sectors.

Please note that SeedFolio Fund 2 is fully invested, and the firm is not seeking new investments at this time. For inquiries, contact invest@seedfolio.vc.